Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma
Authors:
Open Access
- 1 September 2017
- journal article
- review article
- Published by SAGE Publications in Cancer Control
- Vol. 24 (3)
Abstract
Hepatocellular carcinoma (HCC) is an aggressive tumor that often arises in the setting of liver cirrhosis. Although early-stage disease is often amenable for surgical resection, transplant, or locoregional therapies, many patients are diagnosed at an advanced stage or have poor liver reserve. Systemic therapy is the mainstay of treatment for these patients. At present, the only approved therapy for the treatment of advanced disease is the tyrosine multikinase inhibitor sorafenib. Candidacy for treatment is based on liver reserve. Novel agents for the treatment of this disease are urgently needed. In this article, we review systemic therapy trials and upcoming data for the treatment of HCC.Keywords
This publication has 72 references indexed in Scilit:
- Sorafenib versus capecitabine in the management of advanced hepatocellular carcinomaMedical Oncology, 2013
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trialJournal of Hepatology, 2012
- Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenibAlimentary Pharmacology & Therapeutics, 2011
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular CarcinomaJournal of Clinical Oncology, 2008
- Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trialBritish Journal of Cancer, 2007
- Phase II Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2006
- A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular CarcinomaJNCI: Journal of the National Cancer Institute, 2005
- Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis.Journal of Clinical Pathology, 1996
- Overexpression of the MDR1 Gene and P-Glycoprotein in Human Hepatocellular CarcinomaJNCI: Journal of the National Cancer Institute, 1992